Covid-19 in liver transplant recipients: the French SOT COVID registry

• Published in: Clinics and research in hepatology and gastroenterology 2021-07, Vol.45 (4), p.101639-101639, Article 101639
• Main Authors: Dumortier, Jérôme, Duvoux, Christophe, Roux, Olivier, Altieri, Mario, Barraud, Hélène, Besch, Camille, Caillard, Sophie, Coilly, Audrey, Conti, Filomena, Dharancy, Sébastien, Durand, François, Francoz, Claire, Garaix, Florentine, Houssel-Debry, Pauline, Kounis, Ilias, Lassailly, Guillaume, Laverdure, Noémie, Leroy, Vincent, Mallet, Maxime, Mazzola, Alessandra, Meunier, Lucy, Radenne, Sylvie, Richardet, Jean-Philippe, Vanlemmens, Claire, Hazzan, Marc, Saliba, Faouzi
• Format: Article
• Language: English
• Subjects: Adolescent; Aged; Child; Comorbidity; COVID-19; COVID-19 Nucleic Acid Testing; Female; France; Hospitalization; Humans; Immunosuppression; Immunosuppression Therapy; Intensive Care Units; Life Sciences; Liver Transplantation; Male; Middle Aged; Mortality; Original; Pandemics; Prognosis; Registries; Respiration, Artificial; Risk Factors; Transplant Recipients
• ISSN: 2210-7401; 2210-741X
• DOI: 10.1016/j.clinre.2021.101639

•Coronavirus disease-2019 (Covid-19) is an ongoing global pandemic of major concern.•Available data on clinical presentation and prognosis in liver transplant (LT) recipients remains limited.•Disease presentation, immunosuppression management, outcomes, prognostic factors in 104 French LT recipients with Covid-19 are reported.•The composite endpoint of severe Covid-19 within 30 days after diagnosis was reached by 33.0% of the adult patients.•The 30-day mortality rate of adult patients was 20.0%, and 28.1% for hospitalized patients. Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in organ transplant recipients remains limited. The aim of this registry-based observational study was to report the characteristics and clinical outcomes of liver transplant (LT) recipients included in the French nationwide Registry of Solid Organ Transplant Recipients with Covid-19. COVID-19 was diagnosed in patients who had a positive PCR assay for SARS-CoV-2 or in presence of typical lung lesions on imaging or specific SARS-CoV-2 antibodies. Clinical and laboratory characteristics, management of immunosuppression, treatment for Covid-19, and clinical outcomes (hospitalization, admission to intensive care unit, mechanical ventilation, or death) were recorded. Of the 104 patients, 67 were admitted to hospital and 37 were managed at home (including all 13 children). Hospitalized patients had a median age of 65.2 years (IQR: 58.1 − 73.2 years) and two thirds were men. Most common comorbidities included overweight (67.3%), hypertension (61.2%), diabetes (50.7%), cardiovascular disease (20.9%) and respiratory disease (16.4%). SARS-CoV-2 infection was identified after a median of 92.8 months (IQR: 40.1 − 194.7 months) from LT. During hospitalization, antimetabolites, mTOR inhibitor, and CNIs were withdrawn in 41.9%, 30.0% and 12.5% of patients, respectively. The composite endpoint of severe Covid-19 within 30 days after diagnosis was reached by 33.0% of the adult patients. The 30-day mortality rate was 20.0%, and 28.1% for hospitalized patients. Multivariate analysis identified that age was independently associated with mortality. In our large nationwide study, Covid-19 in LT recipients was associated with a high mortality rate.